Allurion Technologies Inc. is ramping up its leadership team, supporting efforts to enter new markets with its Elipse Balloon, a nonsurgical gastric balloon intended to treat patients with obesity. The device was CE-marked in 2015 and is available in 10 countries in Europe and the Middle East, but the company says it is gearing up with the help of new funds to start a US FDA pivotal and expand its commercial presence.
The firm said on Jan. 2 that Shantanu Gaur, a cofounder of Allurion, took on the role of CEO at the start of the new year, while Jonathan Wecker, who...